Literature DB >> 7530747

Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients.

C Ebner1, S Schenk, N Najafian, U Siemann, R Steiner, G W Fischer, K Hoffmann, Z Szépfalusi, O Scheiner, D Kraft.   

Abstract

The immune response toward allergens in nonallergic healthy individuals was investigated. To boost immune responses, two injections of birch pollen extract were administered to five nonallergic volunteers. T cell lines (TCL) with specificity for Bet v 1, the major birch pollen allergen, were established and analyzed for epitope specificity using overlapping peptides. Forty-nine T cell clones (TCC) specific for Bet v 1 were isolated from TCLs. Comparison with TCL and TCC established from birch pollen-allergic patients was performed. All TCC revealed the Th phenotype. Epitope specificities of TCL and TCC from nonatopics were identical to those found in allergic individuals. No association between MHC class II molecules and particular epitopes could be observed. In nonallergic as well as in allergic individuals, cytokine production in response to specific stimulation revealed a majority of Th-clones producing IL-4 and IFN-gamma. However, TCC derived from atopic individuals revealed a higher IL-4/IFN-gamma ratio. Immunoblot and ELISA revealed Bet v 1-specific IgG in nonallergic individuals before and after booster injections, but no IgE could be detected. High levels of Bet v 1-specific IgG and IgE could be detected in birch pollen-allergic patients. It can be concluded, that nonatopic and allergic individuals display the same repertoire of T cell specificities. In allergic individuals, the activation of allergen-specific TCC leads to a higher ratio of produced IL-4 vs IFN-gamma, which is responsible for enhanced IgE production.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7530747

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

Review 1.  Recombinant allergens.

Authors:  C Grégoire; M D Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2001-10       Impact factor: 8.667

Review 2.  Molecular characterization of allergens.

Authors:  S S Mohapatra; R F Lockey
Journal:  Clin Rev Allergy Immunol       Date:  2001-10       Impact factor: 8.667

3.  Use of multiple peptides containing T cell epitopes is a feasible approach for peptide-based immunotherapy in Can f 1 allergy.

Authors:  Anu K Immonen; Antti H Taivainen; Ale T O Närvänen; Tuure T Kinnunen; Soili A Saarelainen; Marja A Rytkönen-Nissinen; Tuomas I Virtanen
Journal:  Immunology       Date:  2007-01       Impact factor: 7.397

4.  Immunodominance in allergic T-cell reactivity to Japanese cedar in different geographic cohorts.

Authors:  Carla Oseroff; John Pham; April Frazier; Denise Hinz; John Sidney; Sinu Paul; Jason A Greenbaum; Randi Vita; Bjoern Peters; Véronique Schulten; Alessandro Sette
Journal:  Ann Allergy Asthma Immunol       Date:  2016-12       Impact factor: 6.347

Review 5.  T-cell epitopes of food allergens.

Authors:  Barbara Bohle
Journal:  Clin Rev Allergy Immunol       Date:  2006-04       Impact factor: 8.667

6.  Effects of adjuvants on the immune response to allergens in a murine model of allergen inhalation: cholera toxin induces a Th1-like response to Bet v 1, the major birch pollen allergen.

Authors:  U Wiedermann; B Jahn-Schmid; R Fritsch; L Bauer; H Renz; D Kraft; C Ebner
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

7.  Epitope analysis of birch pollen allergen in Japanese subjects.

Authors:  Y Abe; S Kimura; T Kokubo; K Mizumoto; M Uehara; M Katagiri
Journal:  J Clin Immunol       Date:  1997-11       Impact factor: 8.317

8.  Antagonism of airway tolerance by endotoxin/lipopolysaccharide through promoting OX40L and suppressing antigen-specific Foxp3+ T regulatory cells.

Authors:  Wei Duan; Takanori So; Michael Croft
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

Review 9.  Antigen-specific immunotherapy of autoimmune and allergic diseases.

Authors:  Catherine A Sabatos-Peyton; Johan Verhagen; David C Wraith
Journal:  Curr Opin Immunol       Date:  2010-09-17       Impact factor: 7.486

Review 10.  Is there a role for treatment of asthma with omalizumab?

Authors:  H Milgrom
Journal:  Arch Dis Child       Date:  2003-01       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.